在高收入国家环境中采用1剂次9价人乳头瘤病毒疫苗接种方案的健康与经济影响建模:英国分析
研究基于英国动态HPV传播感染与疾病模型,估计将13-14岁女孩和男孩的2剂次HPV疫苗接种程序改为超说明书1剂次9价HPV方案的潜在健康与经济结局,并纳入单剂保护持久性和相对保护程度的不确定性。结果显示1剂次方案在100年内较2剂次方案增加81,738例HPV相关癌症,在£20,000/质量调整生命年支付意愿阈值下具有成本效果的概率为7.8%。
要点
- 1剂次9vHPV方案较2剂次方案在100年内增加81,738例HPV相关癌症(范围36,673至134,347例)。
- 1剂次方案在£20,000/质量调整生命年阈值下具有成本效果的概率为7.8%。
- 额外癌症例数对单剂保护持续时间分布中位数和覆盖率敏感。
核心结论
- 采用1剂次9vHPV疫苗接种方案导致男女中更多疫苗可预防的HPV相关癌症和疾病病例,引入健康与经济结局的实质性不确定性,且与2剂次方案相比具有成本效果的概率低。
研究设计与样本
- 研究采用适配英国的动态HPV传播感染与疾病模型,纳入基于估计分布的概率敏感性分析,并对关键输入进行单因素敏感性分析。
- 目标人群为13-14岁女孩和男孩,比较2剂次HPV疫苗接种程序与超说明书1剂次9vHPV方案。
主要发现
- 1剂次方案预测在100年内较2剂次方案在男女中增加81,738例HPV相关癌症病例,范围36,673至134,347例(分别为2.5%和97.5%分位数)。
- 1剂次方案在£20,000/质量调整生命年支付意愿阈值下具有成本效果的概率为7.8%。
- 单因素敏感性分析中,额外癌症例数对单剂保护持续时间分布中位数和覆盖率敏感。
- 净货币效益差异对单剂保护持续时间分布中位数、剂量价格和贴现率敏感,但对覆盖率变化不敏感。
- 在各项敏感性分析中,1剂次方案较2剂次方案在标准支付意愿阈值下具有成本效果的概率均低于50%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although no human papillomavirus (HPV) vaccine is indicated for single-dose administration, some observational evidence suggests that a 1-dose regimen might reduce HPV infection risk to that achieved with 2 doses. This study estimated the potential health and economic outcomes associated with switching from a 2-dose HPV vaccination program for girls and boys aged 13-14 years to an off-label 9-valent (9vHPV), 1-dose regimen, accounting for the uncertainty of the effectiveness and durability of a single dose. A dynamic HPV transmission infection and disease model was adapted to the United Kingdom and included a probabilistic sensitivity analysis using estimated distributions for duration of protection of 1-dose and degree of protection of 1 relative to 2 doses. One-way sensitivity analyses of key inputs were performed. Outcomes included additional cancer and disease cases and the difference in net monetary benefit (NMB). The 1-dose program was predicted to result in 81,738 additional HPV-related cancer cases in males and females over 100 years compared to the 2-dose program, ranging from 36,673 to 134,347 additional cases (2.5% and 97.5% quantiles, respectively), and had a 7.8% probability of being cost-effective at the £20,000/quality-adjusted life years willingness-to-pay (WTP) threshold. In one-way sensitivity analyses, the number of additional cancer cases was sensitive to the median of the duration of protection distribution and coverage rates. The differences in NMBs were sensitive to the median of the duration of protection distribution, dose price and discount rate, but not coverage variations. Across sensitivity analyses, the probability of 1 dose being cost-effective vs 2 doses was < 50% at the standard WTP threshold. Adoption of a 1-dose 9vHPV vaccination program resulted in more vaccine-preventable HPV-related cancer and disease cases in males and females, introduced substantial uncertainty in health and economic outcomes, and had a low probability of being cost-effective compared to the 2-dose program.
引用
- Daniels V, Saxena K, Patterson-Lomba O, et al. Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom. Vaccine. 2022. PMID: 35232593. doi:10.1016/j.vaccine.2022.02.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。